Hahahaha - ye$$$$$$$!

9/11 and JFK theories, get'em started!!

Great start!

Titan's giving us some early fireworks to start off the long weekend.

Hahahaha yes!

Props - I have been thinking the same thing.

M&A could support small-caps and mid-caps

M&A activity has clearly accelerated this year; 246 deals totaling over $1.85 trillion were announced between Feb.6 and June 9, 2014.

Whether that’s a sign of renewed optimism about the economy, or that it’s easier for companies to buy growth than generate it on their own, mid- and small-cap stocks are likely beneficiaries.

Certainly many large-cap companies are in good position to go shopping, with high levels of cash available on their balance sheets and a low-interest rate environment that favors financing. Those factors alone make acquisitions more appealing as a means to capture market share, acquire productive capacity, top off sales volume – and ideally find valuable synergies along the way.

Investors seem to support this strategic use of cash – the stock prices of both acquired companies and the companies making the acquisitions rose 64.0% and 48.3%, respectively over 2013 – significantly more than major market indexes.

*Not a bad sign for a company like Titan.

Can someone "Tag" Point's articles so they are at the top of the Message Board? Or is that not possible?

Thanks!

Renaissance18:

Well said and your input is greatly appreciated. LTG - a rebuttal would only lessen your already diminished credibility.

Hahaha... Winning Renaissance18!

Big surprise RBC and Stifle came out with an "Outperform" and "Buy" on Transenterix... Considering they were the lead underwriters on the most recent Transenterix stock offering.

From the Transenterix Prospectus supplement dated April 2, 2014:

UNDERWRITING
Stifel, Nicolaus & Company, Incorporated and RBC Capital Markets, LLC are acting as joint book-running
managers of the offering and as representatives of the underwriters named below. Subject to the terms and
conditions set forth in an underwriting agreement dated the date of this prospectus supplement, each of the
underwriters named below has severally agreed to purchase from us the aggregate number of shares of common
stock set forth opposite their respective names below:
Underwriters Number of Shares
Stifel, Nicolaus & Company, Incorporated . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5,000,000
RBC Capital Markets, LLC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3,750,000
Ladenburg Thalmann & Co. Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,875,000
Raymond James & Associates, Inc. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1,875,000
Total . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12,500,000
The underwriting agreement provides that the obligations of the several underwriters to purchase the shares of
common stock included in this offering are subject to various conditions, including approval of legal matters by
counsel. The nature of the underwriters’ obligations commits them to purchase and pay for all of the shares of
common stock listed above, other than those covered by the over-allotment option described below, if any are
purchased.
The underwriters expect to deliver the shares of common stock to purchasers on or about April 21, 2014.

What a nice discount the underwriters and "existing stockholders that are affiliated with certain of our directors" received.

Commissions and Discounts
The underwriters propose to offer the shares of common stock directly to the public at the public offering price
set forth on the cover page of this prospectus supplement, and at this price less a concession not in excess of
$0.144 per share of common stock to other dealers. After this offering, the offering price, concessions, and other
selling terms may be changed by the underwriters. Our common stock is offered subject to receipt and
acceptance by the underwriters and to the other conditions, including the right to reject orders in whole or in part.
The following table summarizes the compensation to be paid to the underwriters by us and the proceeds,
before expenses, payable to us:
Per Share
Total
Without
Over-Allotment
With
Over-Allotment
Public offering price . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4.00 50,000,000 57,500,000
Underwriting discount . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 0.24 3,000,000 3,450,000
Proceeds, before expenses, to us . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3.76 47,000,000 54,050,000
S-13
Certain of our existing stockholders that are affiliated with certain of our directors have agreed to purchase
$10,000,000 of our common stock in this offering. The underwriters will receive the same underwriting discount
on these shares purchased by these entities as they will on any other shares sold to the public in this offering.
We estimate that the total expenses of this offering payable by us, excluding underwriting discounts and
commissions, will be approximately $800,000. We have agreed to reimburse the underwriters for certain
expenses in an amount up to $50,000.

Perfect way to sum up Transenterix... From the Transenterix Prospectus supplement dated April 2, 2014:

"We have a history of operating losses, and we may not be able to achieve or sustain profitability. In addition we may be unable to continue as a going concern".

"We are a medical device company with a limited operating history. We are not profitable and have incurred losses since our inception. Substantial doubt exists about our ability to continue as a going concern as a result of recurring losses and an accumulated deficit. We continue to incur research and development and general and administrative expenses related to our operations. Our net loss for the year ended December 31, 2013 was $28.4 million, and our accumulated deficit as of December 31, 2013 was $93.3 million."

"We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we prepare for clinical trials of our products and continue to commercialize our cleared or approved products. If our products fail in clinical trials or do not gain regulatory clearance or approval, or if our products do not achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Absent a significant increase in revenue or additional equity or debt financing, we may not be able to sustain our ability to continue as a going concern. On March 31, 2014, we filed this prospectus as part of a Registration Statement on Form S-3 to register $100,000,000 of our securities for sale from time to time. Once such Registration Statement is declared effective by the SEC, we do anticipate proceeding with offerings of our securities in accordance with the shelf registration statement requirements. We cannot assure you that we will be successful in obtaining such additional financing on terms acceptable to us or at all."

"We will require substantial additional funding, which may not be available to us on acceptable terms, or at We expect to continue to incur losses for the foreseeable future, and these losses will likely increase as we prepare for clinical trials of our products and continue to commercialize our cleared or approved products. If our products fail in clinical trials or do not gain regulatory clearance or approval, or if our products do not achieve market acceptance, we may never become profitable. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. Absent a significant increase in revenue or additional equity or debt financing, we may not be able to sustain our ability to continue as a going concern. On March 31, 2014, we filed this prospectus as part of a Registration Statement on Form S-3 to register $100,000,000 of our securities for sale from time to time. Once such Registration Statement is declared effective by the SEC, we do anticipate proceeding with offerings of our securities in accordance with the shelf registration statement requirements. We cannot assure you that we will be successful in obtaining such additional financing on terms acceptable to us or at all."

" We will require substantial additional funding, which may not be available to us on acceptable terms, or at all."

Read it for yourself at:

www.stifel.com/prospectusfiles/PD_1771.pdf

Gotta feel confident after that read!

Hahaha, good one LTG, I thoroughly enjoyed that one.

Good luck getting an unbiased view on the message boards Lurker.

Best advice is do your own due diligence!

Yes! Everyone, proof read your posts!!

I expected a better day when the news came out as well... But the reality is we are talking about a stock that was trading below $0.40 less than a year ago.

All that matters is the tissue testing was positive and that is a step in the right direction.

Plus, Point is of fire w/ his articles... Fantastic job Point!!!

Can someone post the link that shows when management buys or sells stock.
Thanks!

Fantastic job point!
Very impressive!!

Appreciate it point!

Was anyone else from the board at the meeting today?

Point - How many investors would you say attended?

Come tax time.
No need for any type of withholding when liquidating positions in a non-qualified account.

Looks like Mr. Leon has found himself another company.
Revive Therapeutics LTD
TSXV: RVV

Psh... Craig Leon, what a joker.
All he did was get them on the exchange.

There is absolutely no reason to compare the two company's. They are in completely different situations.

Additionally, let's not take "the other company's" R/S as if Titan's stock would mirror a similar decline in the event of a R/S. We are talking about one other company and it's dangerous to take a sample size of one that serious.

I really don't understand why so many people out there are against a R/S.

With so many shares outstanding there is no doubt Titan will complete a R/S at some point.... I would be happy if they jumped back to the $2.50 territory, created a base and then announced a R/S.

*2. I wish I buy stock on Totes Magotes name.

1. March Madness drops volume on just about all stocks... Especially the first couple days.

2. I wish I could stock in Totes Magotes name.

3. We should all be pleased that Titan is forming a solid base at $2.00 a share.... At least for the time being.

Completely agree.

Let's hope the management is accumulating shares as well - a great sign of confidence for the investors.

I completely agree and appreciate the sound logic.

If you are in this for the long haul there is absolutely no reason to worry.

We saw this coming, it is likely that much of the dilution is already factored in and I believe this creative way of financing was the right way to go.

Everyone needs to relax, take a deep breath and stop acting like day traders.

Alive - days like this are bound to happen w/ any stock.

Could simply be the calm before the storm (in a good way.)

Good to hear LTG - look forward to your article.

I understand you feel as if some have been quite childish - but please don't act like it is that easy to time a stock.... Saving a quick 10% on dilution is not worth the possible loss of gains you could miss out on during that period.

Good point whassup.

I would assume day traders that got in on Friday or earlier today.

Another solid day - great to see!

It must be said again... These gains have all been gained with no PR. One can only imagine what will be seen once new information is released by Titan.

I agree with you Bob.

I believe 15.00 - 20.00 share price is realistic and feasible if the pieces come together properly.

A stock at $5.00 or below is considered a "penny stock" by institutions.

A ways to go - but, w/ what we've seen as of late that may be sooner than later.

Ooooooooooh baby!

It's begins.

ISRG up big today on news.
As this is positive press for all robotic surgery companies (current and prospective) surprised we aren't seeing a little pop from the others today.

Cheers to Titan's 2014 success thus far - looking forward to the coming years!

P.S. - If you are own and believe in this stock you have already factored in the dilution in the future! No worries!!

Hahaha - this is classic.

Hey!
I get no respect?! Ha.

I have 98,100 shares, average cost basis of $0.72.

Started buying a couple years back.

Kev63 has a good point.

A reverse split will definitely happen at some point - simply look at the number of shares that are currently outstanding..... BUT, a reverse split is not necessarily a bad thing.

Strong Buy on Titan, just need to have patience.

Classic.

Investors panicking today as we see lower volume and less talk.

Thank goodness for idiots.

Great work Ichauway -

New set-up is lookin' good!

Thanks Ichauway! Appreciate it!!